SPS
AVIR icon

Susquehanna Portfolio Strategies’s Atea Pharmaceuticals AVIR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Buy
62,073
+6,586
+12% +$32.8K ﹤0.01% 750
2026
Q1 		$299K Buy
+55,487
New +$255K ﹤0.01% 841
2024
Q2 		– Sell
-80,830
Closed -$327K – 534
2024
Q1 		$327K Sell
80,830
-2,445
-3% -$9.57K 0.01% 651
2023
Q4 		$254K Buy
+83,275
New +$252K ﹤0.01% 891

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Portfolio Strategies's AVIR Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Atea Pharmaceuticals (AVIR) stake by 12% in Q2 2026, buying an estimated $32.8K and bringing the position to 62,073 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

Susquehanna Portfolio Strategies first reported a position in AVIR in Q4 2023 and has held it in 4 quarters since. The position peaked at $327K in Q1 2024. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Susquehanna Portfolio Strategies held 62,073 shares of Atea Pharmaceuticals worth $289K as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 6,586 Atea Pharmaceuticals shares in Q2 2026, an estimated $32.8K.
  • Atea Pharmaceuticals made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #750 holding.
  • Susquehanna Portfolio Strategies first reported a position in Atea Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Atea Pharmaceuticals position peaked at $327K in Q1 2024.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.